Acadia Pharmaceuticals Stock Trading Halted Today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Goldman Sachs on Acadia Pharmaceuticals (ACAD): 'We expect the stock to move lower on Tuesday given the results of the vote'
June 21, 2022 10:18 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Neutral rating and $20.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD)
The analyst comments "The FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) voted against pimavanserin (Nuplazid) as an effective treatment for hallucinations and delusions in Alzheimer's disease psychosis (ADP) (Vote: 9 No/3 Yes), and recommended... More
Acadia Pharma (ACAD) Resume Trading, Down 32%
June 21, 2022 7:11 AM EDTAcadia Pharma (NASDAQ: ACAD) Resume Trading, Down 32%
... More